Showing 3991-4000 of 5623 results for "".
- Nanodropper Launches 2022 Give the Gift of Vision Campaign to Support Global Access to Eye Carehttps://modernod.com/news/nanodropper-launches-2022-give-the-gift-of-vision-campaign-to-support-global-access-to-eye-care-1/2481275/Nanodropper has launched its 2022 Give the Gift of Vision program, an effort to donate 1,000 Nanodropper Adaptors to at-need patients in the United States and its global nonprofit partners, aiming to deliver better access to vision-saving care in low resource settings in Africa, Haiti, and e
- Improved PC-IOL Technology is Key to Recent and Future Premium Cataract Surgery Growthhttps://modernod.com/news/improved-pc-iol-technology-is-key-to-recent-and-future-premium-cataract-surgery-growth/2481273/Presbyopia-correcting IOL technology improvements have led to almost a doubling of global units over the past 5 years and will be critical to driving future growth over the next 5 years, according to a Market Scope report. In 2022, PC-IOLs will represent nearly 55 percent of premi
- Cognition Therapeutics Presents Data Supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-presents-data-supporting-a-phase-2-clinical-trial-with-ct1812-in-geographic-atrophy-secondary-to-dry-amd/2481270/Cognition Therapeutics announced that the scientific rationale, supporting proof-of-concept data and design of the planned phase 2 trial of CT1812 in geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) will be communicated in an oral presentation at the
- RetinAI Launches Discovery CORE: AI Platform for Retinal Fluid and Layer Segmentationhttps://modernod.com/news/retinai-launches-discovery-core-ai-platform-for-retinal-fluid-and-layer-segmentation/2481269/RetinAI Medical AG has launched Discovery CORE with AI for retinal fluid and layer segmentation. Discovery CORE and its AI models have been designed to accelerate data analysis and help clinical and academic researchers collaborate more efficiently in real time with their peers on medical and ima
- Ripple Therapeutics Appoints Jonathan Talamo, MD, to Chair of the Boardhttps://modernod.com/news/ripple-therapeutics-appoints-jonathan-talamo-md-to-chair-of-the-board/2481265/Ripple Therapeutics announced that Jonathan Talamo, MD, has been appointed as the new Chair of its Board of Directors. Dr. Talamo is internationally known as an experienced surgeon and thought leader in ophthalmology. Following 25 years in clinical practice, Dr. Talamo s
- New UCI-Led Study Shows Repeated Stress Accelerates Aging of the Eyehttps://modernod.com/news/new-uci-led-study-shows-repeated-stress-accelerates-aging-of-the-eye/2481260/New research from the University of California, Irvine, suggests aging is an important component of retinal ganglion cell death in glaucoma, and that novel pathways can be targeted when designing new treatments for glaucoma patients. The study, titled, “
- Meivertor Single-Handed Upper and Lower Eyelid Eversion Tool Now Availablehttps://modernod.com/news/meivertor-single-handed-upper-and-lower-eyelid-eversion-tool-now-available/2481259/Introduced at the American Academy of Optometry meeting in San Diego, the Meivertor is designed to be a simple solution for an everyday challenge: eversion of the upper eyelid to image the meibomian glands. "Having images of the meibomian glands is important to
- Alcon Completes Acquisition of Aerie Pharmaceuticalshttps://modernod.com/news/alcon-completes-acquisition-of-aerie-pharmaceuticals/2481258/Alcon announced that it has completed its acquisition of Aerie Pharmaceuticals. In August, Alcon announced its was acquiring Aerie for about $770 million, or $15.25 per share—a premium of 37% to Aerie’s closing price prior to the deal. The deal bolsters Alcon's
- Study: Form of AMD Strongly Associated With Cardiovascular Diseasehttps://modernod.com/news/study-blinding-eye-disease-strongly-associated-with-serious-forms-of-cardiovascular-disease/2481254/Patients with a specific form of age-related macular degeneration (AMD) are also highly likely to have either underlying heart damage from heart failure and heart attacks, or advanced heart valve disease, or carotid artery disease associated with certain types of strokes, according to a new study
- Sightpath Medical Acquires Accusite Surgicalhttps://modernod.com/news/sightpath-medical-acquires-accusite-surgical/2481253/Sightpath Medical announced that it has acquired Accusite Surgical, a cataract surgery equipment outsourcing company. Terms of the deal were not disclosed. Founded in 1991, Sightpath Medical delivers custom access to ophthalmic equipment, instruments, and services. Through its patented